- Working with InhibOx
The Cambridge Crystallographic Data Centre (CCDC) supports drug discovery through its industry-standard Cambridge Structural Database (CSD), containing more than half a million small molecule crystal structures, and through knowledge-based tools to support receptor modeling, ligand design, docking, lead optimization and formulation studies. Its database and modeling systems are in use at research operations worldwide, including at all of the world’s top pharmaceutical companies.
The combined InhibOx-CCDC service offers pharmaceutical, biotech and governmental research organizations access to new capabilities to accelerate drug discovery and improve productivity. It includes full-spectrum computer-aided drug discovery (CADD) from receptor site studies, through lead identification, lead optimization, and formulation modeling. The new service offers life science companies a step-change in the quality and effectiveness of CADD services through the use of leading proprietary technologies and databases, applied by scientists with deep commercial drug discovery experience.
Intelligensys enables companies involved in product formulation and process development to realize business potential by providing software that unlocks the value in existing experimental data.
Intelligensys was founded in 1999, building on activities pioneered within ICI PLC, Zeneca PLC, and Oxford Materials Ltd. The core applications of Intelligensys artificial intelligence technology focused initially on product formulation. Since then, Intelligensys has grown to encompass selected areas of simulation to Pharma, Chemical, Coatings and Academic sectors. It has a worldwide customer base.
InhibOx is collaborating with Intelligensys to develop new applications of its technology to drug discovery, in particular virtual screening and the prediction of physicochemical properties.
COSMIC Discoveries’ diverse medicinal and synthetic chemistry expertise spans major therapeutic areas and numerous disease-relevant targets and mechanisms. Its medicinal and computational chemists have developed multiple pre-clinical drug candidates from early leads and hits in a wide variety of therapeutic areas.
COSMIC Discoveries is an independent service organization, associated with the Institute of Life Sciences, Hyderabad. It provides technical and innovative support to significantly enhance the medicinal chemistry efforts of Global Pharma, Biotechs, Research Institutes and Academic Research Centers. COSMIC Discoveries was founded by Prof. Javed Iqbal, who is also the Director of Institute of Life Sciences, and derives its scientific core from the strong research base in the ILS. At COSMIC Discoveries, the diverse medicinal and synthetic chemistry expertise spans major therapeutic areas and numerous disease-relevant targets. It is COSMIC’s vision to be a globally recognized and preferred partner in providing cutting-edge services in organic, medicinal & innovative chemistry.
Molport is a rare chemical compound marketplace enabling worry-free centralized ordering of chemicals from over 200 companies. To make the marketplace work Molport has created a world class database of commercially available chemical compounds. The free access online search portal www.molport.com features unmatched advanced chemical structure search capabilities that are especially suited for a sophisticated and demanding user.
Through its alliance with Molport, InhibOx provides a vertically integrated solution, providing physical screening samples of compounds identified by its computational technology.